Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.

Ivan O RosasGeorge DiazRobert L GottliebSuzana M LoboPhilip RobinsonBradley D HunterAdilson W CavalcanteJ Scott OvercashNicola A HananiaAlan SkarbnikJulia Garcia-DiazIvan GordeevJordi CarratalàOliver GordonEmily GrahamNicholas Lewin-KohLarry TsaiKatie TuckwellHuyen CaoDiana BrainardJulie K Olsson

Published in: Intensive care medicine (2021)

Tocilizumab plus remdesivir did not shorten time to hospital discharge or "ready for discharge" to day 28 compared with placebo plus remdesivir in patients with severe COVID-19 pneumonia.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
juvenile idiopathic arthritis
early onset
rheumatoid arthritis patients
respiratory syndrome coronavirus
community acquired pneumonia
randomized controlled trial
clinical trial
intensive care unit
double blind
extracorporeal membrane oxygenation